Opdivo

(Nivolumab)

Phase 3Monoclonal antibody

Nivolumab is used to treat certain types of cancer, including melanoma, lung cancer, and kidney cancer, by helping the body's immune system recognize and attack cancer cells.[1] Opdivo is currently being investigated across 238 indications[3], with its most advanced program in Phase 3.[1]

Opdivo is one of 2350 monoclonal antibody programs targeting Tracheal Squamous Cell Carcinoma. It is currently in Phase 3.

238

Indications

1,490

Total Trials

Active Trials

2,349

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Tracheal Squamous Cell CarcinomaActive, not recruiting

GliomaActive, not recruiting

Childhood CancerUnknown

Head and Neck CarcinomaActive, not recruiting

Pancreatic NeoplasmActive, not recruiting

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

ChordomaActive, not recruiting

AscitesActive, not recruiting

Urinary Bladder CarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

Tracheal Squamous Cell CarcinomaPhase 2

Active, not recruiting

GliomaPhase 1

Active, not recruiting

Childhood CancerPreclinical

Unknown

Head and Neck CarcinomaPhase 3

Active, not recruiting

Pancreatic NeoplasmPhase 1

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Active, not recruiting

ChordomaPhase 1

Active, not recruiting

AscitesPreclinical

Active, not recruiting

Urinary Bladder CarcinomaPhase 2

Active, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

Showing 10 of 238 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

22 2

Prolia

Amgen

Preclinical

14 3

Adenocard

Astellas

Preclinical

1 4

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Avastin

Roche

Preclinical

4 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 9

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 10

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Active, not recruiting

Metastatic Colorectal Cancer

NCT04599140

Phase 1/2Active, not recruiting

Small Cell Lung Cancer

NCT03377023

Phase 2Recruiting

Salivary Gland Carcinoma

NCT05727410

Phase 2Active, not recruiting

Locally Advanced

NCT03282344

Phase 2Recruiting

Richter's Transformation

NCT05672173

Phase 2Active, not recruiting

Merkel Cell Carcinoma

NCT03071406

Clinical

Trials by Indication[1]

Melanoma20 trials

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

Recruiting·RReplimune Inc.·Phase 3·NCT06264180·400 enrolled

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT01940809·15 enrolled

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03068455·1,844 enrolled

Show 17 more trials

SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma

Recruiting·HHildur Helgadottir·Phase 3·NCT06794775·128 enrolled

Radiation and Combination Immunotherapy for Melanoma

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03850691·4 enrolled

Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION

Terminated·TThe Christie NHS Foundation Trust·Phase 2/3·NCT04901988·8 enrolled

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

Completed·TThe Netherlands Cancer Institute·Phase 1/2·NCT04133948·44 enrolled

Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma

Recruiting·UUppsala University·Phase 3·NCT06488482·1,792 enrolled

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Active, not recruiting·EEmory University·Phase 1·NCT05341349·1 enrolled

SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02716948·17 enrolled

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02320058·119 enrolled

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02910700·52 enrolled

A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT06163170·100 enrolled

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03543969·14 enrolled

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Recruiting·MMassachusetts General Hospital·Phase 2·NCT05779423·37 enrolled

A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases

Completed·UUniversitair Ziekenhuis Brussel·Phase 1/2·NCT02941744·56 enrolled

Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT07079644·678 enrolled

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Recruiting·NNYU Langone Health·Phase 2·NCT05428007·105 enrolled

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT04146324·150 enrolled

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

Completed·NNYU Langone Health·Phase 1·NCT02983006·12 enrolled

Non-Small Cell Lung Cancer13 trials

Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease

Terminated·Hhoward safran·Phase 2·NCT02469701·10 enrolled

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients

Recruiting·UUniversity Hospital, Essen·Phase 2·NCT04205552·90 enrolled

SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects

Completed·RRoyal Marsden NHS Foundation Trust·Phase 1/2·NCT03383302·29 enrolled

Show 10 more trials

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Completed· Pfizer logo

Pfizer··NCT05834348·5,279 enrolled

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02477826·2,747 enrolled

Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer

Withdrawn·EEmory University·Phase 2·NCT03121417

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Active, not recruiting·RRoswell Park Cancer Institute·Phase 1/2·NCT02955290·51 enrolled

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03048136

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03001882·230 enrolled

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Terminated·MMirati Therapeutics Inc.·Phase 2·NCT02954991·161 enrolled

F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer

Unknown status·PPhilogen S.p.A.·Phase 1/2·NCT05468294·3 enrolled

Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Recruiting·HHospital das Clínicas de Ribeirão Preto·Phase 2·NCT07084610·30 enrolled

ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

Completed·MMedical University of South Carolina·Phase 1/2·NCT02523469·67 enrolled

Nivolumab10 trials

A Study of DF6002 Alone and in Combination With Nivolumab

Completed·DDragonfly Therapeutics·Phase 1·NCT04423029·170 enrolled

Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab

No longer available· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT05170685

Nivolumab/Ipilimumab in Second Line CUP-syndrome

Unknown status·UUniversity Hospital Heidelberg·Phase 2·NCT04131621·194 enrolled

Show 7 more trials

Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient

Completed·SSpanish Lung Cancer Group··NCT03132493·676 enrolled

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Unknown status·FFundación de investigación HM·Phase 2·NCT04525638·30 enrolled

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Active, not recruiting·—·Phase 2·NCT03341936·29 enrolled

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04112498·24 enrolled

Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types

Completed·UUNICANCER·Phase 2·NCT03012581·269 enrolled

Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response

Recruiting·EErasmus Medical Center·Phase 4·NCT06116461·34 enrolled

Fedratinib in Combination With Nivolumab

Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05393674·30 enrolled

Lung Cancer5 trials

Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

Completed·IIntergroupe Francophone de Cancerologie Thoracique·Phase 3·NCT03469960·265 enrolled

Repositioning Immunotherapy in VetArans With Lung Cancer

Recruiting·VVA Office of Research and Development·Phase 2·NCT06275360·25 enrolled

BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

Completed·LLung Cancer Group Cologne·Phase 2·NCT03083691·90 enrolled

Show 2 more trials

A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy

Unknown status·GGuangdong Association of Clinical Trials··NCT04306042·1,000 enrolled

TG4010 and Nivolumab in Patients With Lung Cancer

Completed·MMegan Daly, MD·Phase 2·NCT02823990·13 enrolled

Prostate Cancer5 trials

Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)

Unknown status·HHospital Moinhos de Vento·Phase 2·NCT03040791·38 enrolled

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04100018·1,030 enrolled

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

Active, not recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT03600350·19 enrolled

Show 2 more trials

PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02933255·24 enrolled

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Unknown status·SSpanish Oncology Genito-Urinary Group·Phase 2/3·NCT03879122·135 enrolled

105 more indications

Treatment5 trials

A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

Completed·OOlivia Newton-John Cancer Research Institute·Phase 2·NCT02923934·120 enrolled

Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype

Unknown status·CCentre Leon Berard·Phase 3·NCT04741438·96 enrolled

Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT05663710·100 enrolled

Show 2 more trials

Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.

Active, not recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT04730544·96 enrolled

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT04637594·3 enrolled

Small Cell Lung Cancer5 trials

Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer

Terminated·WWake Forest University Health Sciences·Phase 2·NCT03662074·14 enrolled

A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Terminated· AbbVie logo

AbbVie·Phase 1/2·NCT03026166·42 enrolled

Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT03043599·21 enrolled

Show 2 more trials

Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer

Terminated·—·Phase 1·NCT04173325·10 enrolled

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT03377023·66 enrolled

Hepatocellular Carcinoma5 trials

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03383458·545 enrolled

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

Completed·NNational Health Research Institutes, Taiwan·Phase 2·NCT03510871·43 enrolled

Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma

Completed·FFuda Cancer Hospital, Guangzhou·Phase 2·NCT04393220·60 enrolled

Show 2 more trials

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04039607·732 enrolled

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT04658147·31 enrolled

Lymphoma4 trials

Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Unknown status·NNational Research Center for Hematology, Russia·Phase 2·NCT05660993·50 enrolled

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Active, not recruiting·—·Phase 2·NCT03749018·30 enrolled

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT03436862·37 enrolled

Show 1 more trial

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Completed·SSt. Petersburg State Pavlov Medical University·Phase 1/2·NCT03343652·30 enrolled

Metastatic Melanoma4 trials

Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia

Recruiting·IInstitute of Oncology Ljubljana·N/A·NCT07422779·100 enrolled

Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma

No longer available· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02186249

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01783938·138 enrolled

Show 1 more trial

SBRT as a Vaccination for Metastatic Melanoma

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04042506

Chemotherapy3 trials

RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting·AAustralasian Gastro-Intestinal Trials Group·Phase 3·NCT04879368·450 enrolled

Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

Active, not recruiting·NNational Cancer Center Hospital East·Phase 1/2·NCT05394740·30 enrolled

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

Terminated·PPatrick Boland·Phase 2·NCT03547999·17 enrolled

Renal Cell Carcinoma3 trials

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06053658·48 enrolled

Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Active, not recruiting·EExelixis·Phase 3·NCT05678673·317 enrolled

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

Terminated·RRoberto Pili·Phase 2·NCT03552380·12 enrolled

Gastric Cancer3 trials

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02935634·190 enrolled

Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer

Completed·YYonsei University·Phase 1/2·NCT05535569·50 enrolled

Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer

Unknown status·—·Phase 2·NCT04782791·30 enrolled

Advanced Solid Tumors3 trials

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Recruiting·MMemgen, Inc.·Phase 1·NCT05076760·40 enrolled

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT06544655·213 enrolled

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

Completed· Astellas logo

Astellas·Phase 1·NCT03565445·190 enrolled

Bladder Cancer3 trials

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03520491·52 enrolled

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Completed·MMatthew Galsky·Phase 2·NCT03558087·76 enrolled

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03661320·855 enrolled

Oral Cavity Cancer2 trials

Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study

Completed·UUniversity Health Network, Toronto·Phase 1·NCT03575598·10 enrolled

CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer

Completed·TThe Clatterbridge Cancer Centre NHS Foundation Trust·Phase 2·NCT03721757·21 enrolled

Acute Myeloid Leukemia2 trials

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Recruiting·MMayo Clinic·Phase 1·NCT03017820·127 enrolled

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02397720·150 enrolled

Merkel Cell Carcinoma2 trials

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03071406·50 enrolled

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Recruiting·MMelanoma Institute Australia·Phase 2·NCT06151236·20 enrolled

Metastatic Colorectal Cancer2 trials

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT04599140·51 enrolled

Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

Withdrawn·UUniversity of Southern California·Phase 1/2·NCT03576963

Liver Cancer2 trials

Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

Completed·RRobin Kate Kelley·Phase 2·NCT03439891·16 enrolled

A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02828124·25 enrolled

Squamous Cell Carcinoma2 trials

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT03370276·95 enrolled

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Completed· Roche logo

Roche·Phase 2·NCT04785820·206 enrolled

Metastatic Solid Tumors2 trials

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Not yet recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT07492680·260 enrolled

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Recruiting·VVivace Therapeutics, Inc·Phase 1/2·NCT04665206·336 enrolled

Pancreatic Cancer2 trials

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

Completed·HHitendra Patel·Phase 2·NCT03697564·2 enrolled

Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer

Active, not recruiting·—·Phase 1·NCT05482451·10 enrolled

Safety and Efficacy2 trials

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

Recruiting·NNational Research Center for Hematology, Russia·Phase 3·NCT06188676·100 enrolled

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT04350463·92 enrolled

Kidney Cancer2 trials

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

Recruiting·MMark Stein·Phase 2·NCT04322955·48 enrolled

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

Completed·UUniversity of California, Davis·Phase 1/2·NCT02899078·31 enrolled

Advanced Cancers2 trials

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT02869789·1,041 enrolled

Study of BMS-986158 in Subjects With Select Advanced Cancers

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02419417·83 enrolled

Urothelial Carcinoma2 trials

Neoadjuvant Nivolumab for Upper Tract Urothelial Carcinoma

Unknown status·YYULISU·Phase 2·NCT05160285·29 enrolled

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Completed·IInfinity Pharmaceuticals, Inc.·Phase 2·NCT03980041·49 enrolled

Breast Cancer2 trials

Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer

Completed·OOslo University Hospital·Phase 2·NCT03409198·82 enrolled

Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer

Terminated·NNorthwestern University·Phase 2·NCT02892734·3 enrolled

Biliary Tract Cancer2 trials

Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients

Completed·HHerlev Hospital·Phase 2·NCT02866383·160 enrolled

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02829918·54 enrolled

Stereotactic Body Radiotherapy1 trial

Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer

Completed·UUniversity of Chicago·Phase 1·NCT03431948·60 enrolled

Genitourinary Cancer1 trial

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT03115801·6 enrolled

Radiation Exposure1 trial

Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02864316·6 enrolled

Leiomyosarcoma1 trial

A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04624178·20 enrolled

Patients With Solid Tumors1 trial

An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03335540·20 enrolled

Advanced or Metastatic Solid Tumors1 trial

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT01928394·1,163 enrolled

Experimental1 trial

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03363776·10 enrolled

Endometrial Cancer1 trial

Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)

Recruiting·YYonsei University·Phase 2·NCT05795244·30 enrolled

Central Nervous System Lymphoma1 trial

Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03770416·18 enrolled

Leukemia1 trial

Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02631746·3 enrolled

Bevacizumab1 trial

Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

Active, not recruiting·DDavid Peereboom·Phase 2·NCT03452579·90 enrolled

Mesothelioma1 trial

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Terminated·—·Phase 2·NCT03502746·34 enrolled

Richter's Transformation1 trial

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Recruiting·—·Phase 2·NCT05672173·20 enrolled

Soft Tissue Sarcoma1 trial

Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma

Completed·KKristen Ganjoo·Phase 2·NCT04118166·30 enrolled

Colorectal Cancer1 trial

Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04457284·18 enrolled

HNSCC1 trial

Intratumoral Microdosing of Motolimod in HNSCC

Terminated·PPresage Biosciences·Phase 1·NCT04272333·1 enrolled

Locally Advanced1 trial

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03282344·88 enrolled

Nab-paclitaxel1 trial

A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

Unknown status·GGuangdong Association of Clinical Trials·Phase 2·NCT04015778·48 enrolled

Urothelial Cancer1 trial

Pre-operative Immunotherapy in Stage II-III Urothelial Cancer

Completed·TThe Netherlands Cancer Institute·Phase 1·NCT04871594·15 enrolled

Olfactory Neuroblastoma1 trial

Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab

Recruiting·NNational Cancer Center Hospital East·Phase 2·NCT07100704·14 enrolled

PET/CT Imaging1 trial

Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction

Unknown status·AAmsterdam UMC, location VUmc·Phase 1·NCT03843515·17 enrolled

Gastrointestinal1 trial

Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers

Withdrawn·UUniversity of California, San Diego·Phase 1/2·NCT05153304

Salivary Gland Cancer1 trial

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Unknown status·NNorthwestern University·Phase 2·NCT03146650·25 enrolled

Metastatic1 trial

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT02496208·152 enrolled

Head and Neck Cancer1 trial

Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)

Completed·GGrupo Español de Tratamiento de Tumores de Cabeza y Cuello·Phase 2·NCT04282109·141 enrolled

Rectal Cancer1 trial

Neoadjuvant Regorafenib in Combination with Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer

Recruiting·JJules Bordet Institute·Phase 2·NCT04503694·72 enrolled

Trial1 trial

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03297606·720 enrolled

Transitional Cell Carcinoma1 trial

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma

Unknown status·AAIO-Studien-gGmbH·Phase 2·NCT03219775·169 enrolled

Cervical Cancer1 trial

BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer

Terminated·—·Phase 2·NCT03527264·4 enrolled

Malignancies1 trial

INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

Recruiting·UUniversity Hospital Heidelberg·Phase 1/2·NCT03838042·91 enrolled

Autoimmune Disorders1 trial

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03816345·300 enrolled

Advanced Stage Cancer1 trial

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting·AAmerican Society of Clinical Oncology·Phase 2·NCT02693535·4,200 enrolled

Overall Survival1 trial

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

Not yet recruiting·GGuliz Ozgun·Phase 3·NCT07338981·142 enrolled

Newly Diagnosed1 trial

Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04401774·14 enrolled

Metastatic Head and Neck Cancer1 trial

HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy

Recruiting·YYonsei University·Phase 2·NCT05280457·21 enrolled

Solid Tumors1 trial

Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02426892·33 enrolled

Hodgkins lymphoma1 trial

Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma

Completed·SSt. Petersburg State Pavlov Medical University·Phase 1/2·NCT03343665·30 enrolled

Pembrolizumab1 trial

Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements

Unknown status·NNational University Hospital, Singapore·Phase 1/2·NCT05175235·10 enrolled

Salivary Gland Carcinoma1 trial

Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade Salivary Gland Carcinoma

Recruiting·MMyung-Ju Ahn·Phase 2·NCT05727410·50 enrolled

Neoadjuvant1 trial

Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

Recruiting·MMelanoma Institute Australia·Phase 2·NCT06999980·494 enrolled

Pilot Study1 trial

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

Terminated·YYale University·Phase 1·NCT03526185·6 enrolled

High Risk1 trial

Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT03347838·19 enrolled

Neuroendocrine Carcinoma1 trial

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Active, not recruiting·—·Phase 1·NCT05262556·15 enrolled

Malignant Pleural Mesothelioma1 trial

Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma

Completed·TThe Netherlands Cancer Institute·Phase 2·NCT03048474·36 enrolled

Cancer1 trial

Immune-checkpoint Inhibitors and Surrogate Endpoints in Cancer Trials (SURROGATE-ICI)

Completed·IInstitut Bergonié··NCT03963518·631 enrolled

Glioblastoma1 trial

Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

Terminated·BBaptist Health South Florida·Phase 2·NCT03430791·5 enrolled

Advanced NSCLC1 trial

Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC

Completed·SShanghai Chest Hospital·Phase 1/2·NCT04507906·21 enrolled

Neoadjuvant Chemotherapy1 trial

Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC

Active, not recruiting·XXiangya Hospital of Central South University·Phase 2·NCT04699721·60 enrolled

Follicular Lymphoma1 trial

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

Active, not recruiting·OOlivia Newton-John Cancer Research Institute·Phase 2·NCT05788081·40 enrolled

Oropharynx Cancer1 trial

Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer

Completed·UUNICANCER·Phase 2·NCT03838263·62 enrolled

Paraganglioma1 trial

A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

Terminated·EEnterome·Phase 1/2·NCT04187404·70 enrolled

Efficacy and Safety1 trial

A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07000149·1,116 enrolled

Renal Cell Cancer1 trial

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Suspended·MMichael B. Atkins, MD·Phase 2·NCT05928806·120 enrolled

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Withdrawn·NNorthwestern University·Phase 2·NCT06247540

Metastatic NSCLC1 trial

Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)

Recruiting·GGazi University··NCT07394062·400 enrolled

Single Dose1 trial

A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128

Active, not recruiting·BBiomica Ltd.·Phase 1·NCT05354102·11 enrolled

Advanced Malignancies1 trial

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Completed·RRedx Pharma Ltd·Phase 1·NCT03447470·46 enrolled

COVID-191 trial

COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1

Unknown status·DDr Gerry Gin Wai Kwok·Phase 2·NCT04356508·15 enrolled

Glioma1 trial

Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03718767·62 enrolled

Vaccines1 trial

First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV

Completed·BBarinthus Biotherapeutics·Phase 1/2·NCT04778904·55 enrolled

Premalignant Lesion1 trial

Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05327270·18 enrolled

Advanced Solid Cancers1 trial

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT04317105·54 enrolled

Adenocarcinoma1 trial

An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 1/2·NCT03371381·12 enrolled

Fallopian Tube Cancer1 trial

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02498600·100 enrolled

Urinary Tract Cancer1 trial

An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02632409·709 enrolled

Esophageal Squamous Cell Cancer1 trial

A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer

Completed·AAIO-Studien-gGmbH·Phase 2·NCT03416244·66 enrolled

Uterine Leiomyosarcoma1 trial

Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02428192·20 enrolled

Gastroesophageal Junction Cancer1 trial

An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02743494·794 enrolled

Clinical Trial1 trial

Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Unknown status·NNational Cancer Centre, Singapore·Phase 1/2·NCT04620954·31 enrolled

Encephalitis1 trial

Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02856451·486 enrolled

Colorectal Carcinoma1 trial

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

Completed·DDiwakar Davar·Phase 2·NCT05061017·13 enrolled

Metastases1 trial

Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion

Recruiting·VVastra Gotaland Region·Phase 1/2·NCT03685890·74 enrolled

Neuroblastoma1 trial

Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma

Active, not recruiting·UUniversity Hospital Southampton NHS Foundation Trust·Phase 1·NCT02914405·44 enrolled

Nasopharyngeal Cancer1 trial

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05904080·50 enrolled

Esophageal Adenocarcinoma1 trial

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Completed·UUniversity of Chicago·Phase 2·NCT02213289·80 enrolled

Combination Therapy1 trial

Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases

Terminated·UUniversity Medical Center Groningen·Phase 2·NCT02621515·7 enrolled

Chemoradiotherapy1 trial

Study to Nivolumab Following Preoperative Chemoradiotherapy

Unknown status·TTakayuki Yoshino·Phase 1/2·NCT02948348·90 enrolled

Advanced Cancer1 trial

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04514484·8 enrolled

Metastatic Cancer1 trial

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

Completed·VVedanta Biosciences, Inc.·Phase 1/2·NCT04208958·56 enrolled

Immune Checkpoint Blockade1 trial

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

Active, not recruiting· Moderna logo

Moderna·Phase 1·NCT06880549·57 enrolled

Kidney Transplant1 trial

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03816332·12 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 22, 2014

Opdivo

BLA 125554

Dec 22, 2014

OPDIVO

BLA BLA125554

Sources

References

[1]
ClinicalTrials.gov — 1490 trial records for Nivolumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nivolumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nivolumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA 125554). U.S. Food & Drug Administration.
[5]
PubMed — 3 publications indexed for Nivolumab. U.S. National Library of Medicine.
[6]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: PD-1 Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Key Publications[5]

Perioperative Nivolumab in Resectable Lung Cancer: CheckMate 816

N Engl J MedNov 17, 2022DOI: 10.1056/NEJMoa2215530

Nivolumab Plus Ipilimumab in Advanced Melanoma: CheckMate 067 Six-Year Results

J Clin OncolJan 13, 2022DOI: 10.1200/JCO.21.02229

Nivolumab in Previously Treated Advanced Hepatocellular Carcinoma

JAMA OncolDec 9, 2021DOI: 10.1001/jamaoncol.2021.5727